Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A404GA | ISIN: US9282512063 | Ticker-Symbol:
NASDAQ
26.04.24
15:30 Uhr
3,050 US-Dollar
+0,180
+6,27 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRPAX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VIRPAX PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur VIRPAX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.04.Virpax Pharmaceuticals files to sell common stock and warrants1
18.04.Virpax Pharmaceuticals, Inc. - S-1, General form for registration of securities1
05.04.Virpax Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
03.04.Virpax Pharmaceuticals, Inc. - 8-K, Current Report1
26.03.Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.771
26.03.Virpax Pharmaceuticals, Inc. - 10-K, Annual Report1
26.03.Virpax Pharmaceuticals, Inc. - 8-K, Current Report4
26.03.Virpax Pharmaceuticals Reports 2023 Year-End Results80BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic...
► Artikel lesen
18.03.Virpax Pharmaceuticals, Inc. - 8-K, Current Report-
15.03.Scilex Pharma Enters Definitive Mutual Release And Settlement Agreement With Virpax-
15.03.Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Su319PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue generating company focused on acquiring, developing and commercializing...
► Artikel lesen
01.03.Virpax Pharmaceuticals, Inc. - 8-K, Current Report2
27.02.Scilex and Sorrento Therapeutics settle with Virpax and its founder Anthony Mack9
27.02.Virpax Pharmaceuticals announces 1-for-10 reverse stock split1
27.02.Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price176BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic...
► Artikel lesen
26.02.Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement98PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
29.12.23Virpax Pharmaceuticals shareholders okay reverse stock split2
29.12.23Virpax Pharmaceuticals, Inc. - 8-K, Current Report1
29.12.23Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting170BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic...
► Artikel lesen
07.12.23Virpax Pharmaceuticals, Inc. - 8-K, Current Report-
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1